ECSP21003707A - Forma de dosificación farmacéutica administrable por vía oral con liberación modificada - Google Patents

Forma de dosificación farmacéutica administrable por vía oral con liberación modificada

Info

Publication number
ECSP21003707A
ECSP21003707A ECSENADI20213707A ECDI202103707A ECSP21003707A EC SP21003707 A ECSP21003707 A EC SP21003707A EC SENADI20213707 A ECSENADI20213707 A EC SENADI20213707A EC DI202103707 A ECDI202103707 A EC DI202103707A EC SP21003707 A ECSP21003707 A EC SP21003707A
Authority
EC
Ecuador
Prior art keywords
diseases
orally administered
modified release
pharmaceutical dosage
dosage form
Prior art date
Application number
ECSENADI20213707A
Other languages
English (en)
Inventor
Donald Bierer
Tia Jacobs
Danja Grossbach
Philipp Rubenbauer
Julia Küsel
Anke Stroyer
Peter Serno
Carmen Lobback
Heiko Schirmer
Kai Lovis
Britta Olenik
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of ECSP21003707A publication Critical patent/ECSP21003707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a formas de dosificación farmacéutica de liberación modificada que pueden administrarse por vía oral que contienen ciclopropilpropanoato de sodio-(3S)-3-(4-cloro-3-{[(2S,3R)-2-(4-clorofenil)-4,4,4,4-trifluoro-3-metilbutanoil]amino}fenil)-3 así como procesos para la preparación de las formas de dosificación y su uso para el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o la prevención de enfermedades cardíacas, renales, pulmonares y oftalmológicas, enfermedades del sistema nervioso central, enfermedades fibróticas e inflamatorias y enfermedades metabólicas.
ECSENADI20213707A 2018-07-24 2021-01-18 Forma de dosificación farmacéutica administrable por vía oral con liberación modificada ECSP21003707A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
EP18185127 2018-07-24

Publications (1)

Publication Number Publication Date
ECSP21003707A true ECSP21003707A (es) 2021-02-26

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20213707A ECSP21003707A (es) 2018-07-24 2021-01-18 Forma de dosificación farmacéutica administrable por vía oral con liberación modificada

Country Status (22)

Country Link
EP (1) EP3826627B1 (es)
JP (1) JP2021532113A (es)
KR (1) KR20210035235A (es)
CN (1) CN112469402B (es)
AU (1) AU2019311234A1 (es)
BR (1) BR112020026644A2 (es)
CA (1) CA3107169A1 (es)
CL (1) CL2021000160A1 (es)
CO (1) CO2021000450A2 (es)
CR (1) CR20210043A (es)
DO (1) DOP2021000015A (es)
EC (1) ECSP21003707A (es)
IL (1) IL280083A (es)
JO (1) JOP20210019A1 (es)
MA (1) MA53368A (es)
MX (1) MX2021000904A (es)
PE (1) PE20210415A1 (es)
PH (1) PH12021550170A1 (es)
SG (1) SG11202100369WA (es)
TW (1) TW202019402A (es)
UY (1) UY38308A (es)
WO (1) WO2020020789A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
EP4339184A4 (en) * 2021-05-14 2025-05-28 Medshine Discovery Inc. ALKYLCARBOXYLIC ACID COMPOUNDS AND THEIR APPLICATION
CA3258617A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN
CN117982443B (zh) * 2022-10-31 2026-03-06 优辉药业(北京)有限公司 一种达格列净二甲双胍缓释片剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ATE72111T1 (de) 1987-01-14 1992-02-15 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2804470A1 (en) 2010-07-09 2012-01-12 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
US11332435B2 (en) 2017-12-01 2022-05-17 Bayer Pharma Aktiengesellschaft Method for producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4- chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid and the crystalline form thereof for use as a pharmaceutical ingredient

Also Published As

Publication number Publication date
CN112469402A (zh) 2021-03-09
TW202019402A (zh) 2020-06-01
IL280083A (en) 2021-03-01
CA3107169A1 (en) 2020-01-30
SG11202100369WA (en) 2021-02-25
MA53368A (fr) 2021-06-02
CR20210043A (es) 2021-03-09
CN112469402B (zh) 2024-05-14
JP2021532113A (ja) 2021-11-25
DOP2021000015A (es) 2021-02-15
MX2021000904A (es) 2021-03-31
EP3826627C0 (de) 2023-10-18
AU2019311234A1 (en) 2021-02-04
CO2021000450A2 (es) 2021-01-29
BR112020026644A2 (pt) 2021-03-23
PH12021550170A1 (en) 2021-09-13
WO2020020789A1 (de) 2020-01-30
CL2021000160A1 (es) 2021-06-04
EP3826627B1 (de) 2023-10-18
UY38308A (es) 2020-02-28
JOP20210019A1 (ar) 2021-01-24
EP3826627A1 (de) 2021-06-02
KR20210035235A (ko) 2021-03-31
PE20210415A1 (es) 2021-03-04

Similar Documents

Publication Publication Date Title
CL2021000160A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX2024010140A (es) Nuevos metodos.
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
BR112015018168A2 (pt) inibidores de rock suaves
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
EA202190334A1 (ru) Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
MX2019014675A (es) Solucion de levodopa para infusion.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
JOP20200005B1 (ar) تركيبات صيدلية
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
JOP20200282A1 (ar) مركب جديد ينطوي على نشاط مثبط للإنتيروببتيداز
EA202092756A1 (ru) Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30